Text Size

Prospective natural history and clinical biomarkers of EYS-associated retinopathy in the KEYS study

Taniguchi M, Togashi Y, Yokota S, Hiraoka M, Kitahata S, Nakamura N, Yamamoto M, Mandai M, Gocho K, Toshimori M, Hirami Y, Gomi F, Kurimoto Y, Maeda A.


  • 2026
  • Scientific Reports
View publication
  • Therapeutic Area

    Back of the eye (BOTE)

  • Categories

    Disease understanding (epidemiology, diagnosis, QoL, Biomarkers…), Sponsored/funded by Santen

  • Affiliations

    Hyogo Medical University Hospital, Nishinomiya, Japan. hirota.mrk@gmail.com.; Kobe City Eye Hospital, Kobe, Japan. hirota.mrk@gmail.com.; Santen Pharmaceutical Co., Ltd, Osaka, Japan; Kobe City Eye Hospital, Kobe, Japan; Kobe City Medical Center General Hospital, Kobe, Japan; Yokohama City University Medical Center, Yokohama, Japan; Quinze-Vingts National Eye Hospital, Paris, France; Hyogo Medical University Hospital, Nishinomiya, Japan.

Related Publications

Cost-Effectiveness Analysis of Low-Dose Atropine Eye Drops (0.01%) for the Treatment of Myopia in Children: A United Kingdom Perspective

Shi-van Wielink K., Dahlmann-Noor A., Li J., de Milliano T.W.L., Ernst F., Croci F., Sharma Y., Punekar Y.


Two-year prospective natural history study of EYS-associated retinitis pigmentosa using adaptive optics: the KEYS study

Masakazu H., Akiko M., Midori Y., Elena G.-S., Shohei K., Satoshi Y., Yuki T., Masanao T., Shuhei K., Yasuhiko H., Yasuo K., Kiyoko G.


STudy of Atropine to Reduce (STAR) Myopia Progression in Children: 24‑Month Results of a Randomized, Double‑Masked, Vehicle‑Controlled Trial of Atropine Sulfate 0.01% and 0.03%

Korenfeld M.; Hurcikova M.; Tatsuoka K.; Cheetham J.; Kacerik M.; on behalf of the STAR Study Investigators


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022